Otsuka Pharmaceutical Company, Limited

Yoshikatsu Hirai

Satoru Nakai

Kazuyoshi Kawai

Mayumi Kaneta

Yeong-Man Hong

Yasuo Yanagihara

Setsuko Takegata

Kiyoshi Ishii

Yoshikazu Kikumoto

Masayuki Takahashi

Koutoku Aihara

Takashi Kamogashira

Yoshihiro Masui

Tadamitsu Kishimoto

Yuichi Yamamura

Hiroyuki Ichikawa

Hiroo Imura

Yasuo Nakayama

Osamu Sato

Setsuyoshi Uetsuki

Naomi Kouno

Tohru Hirato

Yasue Konishi

Junichi Fukata

A homogeneous interleukin 1.beta. (IL-1.beta.), its derivative having a modified amino acid sequence of IL-1.beta., a gene coding for said derivative, medical composition comprising said derivative as a pharmaceutically effective component and a medicinal use of homogeneous IL-1.beta. and the derivative.

IL-1.beta. and derivatives thereof and drugs

This invention provides an anti-tumor agent and a method for treating a tumor wherein gamma-interferon and interleukin-1 are used as active ingredients.

Method of treating colon, renal, and lung carcinomas with

DNA encoding interleukin IL-1.beta. mutant

This invention provides medical uses of a M-CSF, particularly a method and composition for treating inflammatory disease and allergy using natural M-CSF or recombinant M-CSF or the derivatives thereof.

Methods of treating allergies with M-CSF

The present invention provides a medicament for treating thrombocytopenia comprising as an active component at least one polypeptide selected from IL-1 and derivative thereof and a Il-1.alpha. derivative having an amino acid sequence of the formula (.alpha.) which is so modified as to fulfill at least one of the requirements of: deletion of the 16-position Arg; replacement of the 16-position Arg by another amino acid residue; deletion of the sequence of the 1-position Ser to the 14-position Phe and deletion of the amino acid sequence of the 1-position Ser to the 15-position Met.

IL-1.alpha. derivatives

Methods are disclosed for promoting production of colony stimulating factor and inhibiting growth of Meth A tumor cells comprising administering a pharmaceutically effective amount of modified IL-1.alpha. to a subject.

Methods of use of IL-1.alpha.

This invention relates to a biologically active recombinant human M-CSF obtained by expressing a human M-CSF gene coding for the amino acid sequence of the formula (1) in its entirety or devoid of a portion thereof; a process for preparing the recombinant human M-CSF; an expression plasmid containing the human M-CSF gene defined above; and a transformant haboring the above expression plasmid.

DNA encoding human colony-stimulating factors

Methods for stimulating immunity, inhibiting tumor growth, promoting production of a cytokine, and preventing or inhibiting radiation injury by administration of Interleukin-1.alpha. (IL-1.alpha.) derivatives, are disclosed.

Method and use of IL-1.alpha.

An interleukin-1.alpha. (IL-1.alpha.) derivative having a modified amino acid sequence of IL-1.alpha., a gene coding for said derivative, medicinal composition comprising said derivative as a pharmaceutically effective component and a medicinal use of homogeneous IL-1.alpha..

Gene that encodes for polypeptides of IL-1.alpha.

The present invention provides a monoclonal antibody characterized in that the antibody has specific reactivity on human IL-1.beta., and a process for producing the antibody. The invention also provides a method for detection of biologically active human IL-1.beta..

Monoclonal antibody specific for human interleukin-1.beta. and method

Interleukin-1.alpha. (IL-1-.alpha.) and derivatives, and their pharmaceutical compositions for use in treating arthritis or inflammation.

Method for treating arthritis or inflammation with Il-1.alpha. or

Interleukin-1.beta. (IL-1.beta.) and derivatives, and their pharmaceutical compositions for use in treating arthritis or inflammation.

Method of treating arthritus or inflammation with IL-1.beta. or

A method for testing the inducibility of the hypothalamus to effect the secretion of andrenocorticotropic hormone comprising the steps of:

Method for stimulating the secretion of ACTH by administration of IL-1B

The present invention provides a medicament for treating thrombocytopenia comprising as an active component at least one polypeptide selected from IL-1 and derivative thereof and a IL-1.alpha. derivative having an amino acid sequence of the formula (.alpha.) which is so modified as to fulfill at least one of the requirements of: deletion of the 16-position Arg; replacement of the 16-position Arg by another amino acid residue; deletion of the sequence of the 1-position Ser to the 14-position Phe and deletion of the amino acid sequence of the 1-position Ser to the 15-position Met.

Growing community of inventors

Tokushima, Japan

Yoshikatsu Hirai